2020-China's Biomedicine Ushers in the Upsurge of Listing

Categories:最新消息
Author:华讯知识产权
Origin:
Time of issue:2020-11-20 13:53
Views:

(Summary description)Affected by the COVID-19, global IPO activity slows down in 2020. But this year is a glorious year for China's biomedical companies. Since 2018, the Hong Kong Exchanges and Clearing Limited (HKEx) has opened its doors for the first time to biotechnology companies that have no operating income. In 2019, The Science and Technology Innovation Board (STAR Market) established by the Shanghai Stock Exchange has been officially opened for trading. It has brought new vitality to China's capital market and the development of China's technology.. The HKEx and STAR Market have become the first choice for many Chinese unprofitable biomedical companies to list. According to incomplete statistics, as of Nov 20, at least 13 Chinese biopharmaceutical companies have been listed on the HKEx and 10 companies have been listed on the STAR Market. See the table below for details: S/N Company name Stock Exchange Capital Raised Business area 1 Akeso,Inc HKEx Over $300 million Tumour、Autoimmune disease 2 Innocare HKEx About HK$2.093 billion Cancer、Autoimmune disease 3 Kintor Pharmaceutical Limited HKEx About $240 million Prostate Cancer、Breast Cancer Liver cancer、Baldness 4 Zai Lab Limited HKEx HK$5.73 billion Tumour、Autoimmune disease 5 Immunotech Biopharm Ltd HKEx HK$1.0241 billion T-Cell Immunotherapy 6 Ocumension Therapeutics HKEx HK$1.553 billion Ophthalmology 7 Hepalink HKEx HK$3.8 billion Heparin、Tumour 8 Jhbp (Cy) Holdings Limited HKEx ----- Tumour、Autoimmune disease 9 Everest Medicines Limited HKEx ----- Tumour、Autoimmune disease Cardiorenal diseases Infectious disease 10 Simcere Pharmaceutical Group Limited HKEx ----- Tumour、Central nervous system diseases、Autoimmune disease 11 Jw (Cayman) Therapeutics Co. Ltd HKEx ----- CAR-T 12 Remegen Co. Ltd. HKEx ----- Autoimmune disease、Tumour Ophthalmology 13 Antengene Corporation Limited HKEx ----- Tumour 14 Zelgen STAR Market About ¥2.026 billion Tumour、Hematopathy Hepatobiliary disease 15 Bio-Thera Solutions, Ltd STAR Market About ¥2.0 billion Tumour、Autoimmune disease 16 Sinocelltech Grou Limited STAR Market About ¥1.282 billion Monoclonal Antibody Recombination Protein、Vaccine 17 HitGen Inc. STAR Market About ¥830 million The lead drug 18 Cansino Biologics Inc. STAR Market About ¥5.2 billion Vaccine 19 Sunshine Guojian Pharmaceutical(shanghai) Co. Ltd. STAR Market ¥3.183 billion Antibody 20 Jiangsu Aidea Pharmaceutical Co.,ltd STAR Market ¥839.4 million Antidote、Tumour 21 Junshi BiosciencesCo., Ltd. STAR Market About ¥2.7 billion Tumour、Chronic disease Autoimmune disease 22 Easton BioPharmaceuticals Co.,Ltd STAR Market ¥1.335 billion Combination of generic drug development 23 Frontier Biotechnologies Inc STAR Market ¥1.845 billion AIDS antiviral treatment. Pain therapy In addition to the companies listed in the above table, other biopharmaceutical companies such as Beijing Science Sun Pharmaceutical Co.,LTD、Changchun BCHT Biotechnology Co and other companies have also submitted IPO applications to the HKEx and the STAR Market

2020-China's Biomedicine Ushers in the Upsurge of Listing

(Summary description)Affected by the COVID-19, global IPO activity slows down in 2020. But this year is a glorious year for China's biomedical companies.

Since 2018, the Hong Kong Exchanges and Clearing Limited (HKEx) has opened its doors for the first time to biotechnology companies that have no operating income. In 2019, The Science and Technology Innovation Board (STAR Market) established by the Shanghai Stock Exchange has been officially opened for trading. It has brought new vitality to China's capital market and the development of China's technology.. The HKEx and STAR Market have become the first choice for many Chinese unprofitable biomedical companies to list.

According to incomplete statistics, as of Nov 20, at least 13 Chinese biopharmaceutical companies have been listed on the HKEx and 10 companies have been listed on the STAR Market. See the table below for details:

S/N

Company name

Stock Exchange

Capital Raised

Business area

1

Akeso,Inc

HKEx

Over $300 million

Tumour、Autoimmune disease

2

Innocare

HKEx

About HK$2.093 billion

Cancer、Autoimmune disease

3

Kintor Pharmaceutical Limited

HKEx

About $240 million

Prostate Cancer、Breast Cancer

Liver cancer、Baldness

4

Zai Lab Limited

HKEx

HK$5.73 billion

Tumour、Autoimmune disease

5

Immunotech Biopharm Ltd

HKEx

HK$1.0241 billion

T-Cell Immunotherapy

6

Ocumension Therapeutics

HKEx

HK$1.553 billion

Ophthalmology

7

Hepalink

HKEx

HK$3.8 billion

Heparin、Tumour

8

Jhbp (Cy) Holdings Limited

HKEx

-----

Tumour、Autoimmune disease

9

Everest Medicines Limited

HKEx

-----

Tumour、Autoimmune disease

Cardiorenal diseases

Infectious disease

10

Simcere Pharmaceutical Group Limited

HKEx

-----

Tumour、Central nervous system diseases、Autoimmune disease

11

Jw (Cayman) Therapeutics Co. Ltd

HKEx

-----

CAR-T

12

Remegen Co. Ltd.

HKEx

-----

Autoimmune disease、Tumour

Ophthalmology

13

Antengene Corporation Limited

HKEx

-----

Tumour

14

Zelgen

STAR Market

About ¥2.026 billion

Tumour、Hematopathy

Hepatobiliary disease

15

Bio-Thera Solutions, Ltd

STAR Market

About ¥2.0 billion

Tumour、Autoimmune disease

16

Sinocelltech Grou Limited

STAR Market

About ¥1.282 billion

Monoclonal Antibody

Recombination Protein、Vaccine

17

HitGen Inc.

STAR Market

About ¥830 million

The lead drug

18

Cansino Biologics Inc.

STAR Market

About ¥5.2 billion

Vaccine

19

Sunshine Guojian Pharmaceutical(shanghai) Co. Ltd.

STAR Market

¥3.183 billion

Antibody

20

Jiangsu Aidea Pharmaceutical Co.,ltd

STAR Market

¥839.4 million

Antidote、Tumour

21

Junshi BiosciencesCo., Ltd.

STAR Market

About ¥2.7 billion

Tumour、Chronic disease

Autoimmune disease

22

Easton BioPharmaceuticals Co.,Ltd

STAR Market

¥1.335 billion

Combination of generic drug

development

23

Frontier Biotechnologies Inc

STAR Market

¥1.845 billion

AIDS antiviral treatment.

Pain therapy

In addition to the companies listed in the above table, other biopharmaceutical companies such as Beijing Science Sun Pharmaceutical Co.,LTD、Changchun BCHT Biotechnology Co and other companies have also submitted IPO applications to the HKEx and the STAR Market

Categories:最新消息
Author:华讯知识产权
Origin:
Time of issue:2020-11-20 13:53
Views:

Information

Affected by the COVID-19, global IPO activity slows down in 2020. But this year is a glorious year for China's biomedical companies.

Since 2018, the Hong Kong Exchanges and Clearing Limited (HKEx) has opened its doors for the first time to biotechnology companies that have no operating income. In 2019, The Science and Technology Innovation Board (STAR Market) established by the Shanghai Stock Exchange has been officially opened for trading. It has brought new vitality to China's capital market and the development of China's technology.. The HKEx and STAR Market have become the first choice for many Chinese unprofitable biomedical companies to list.

According to incomplete statistics, as of Nov 20, at least 13 Chinese biopharmaceutical companies have been listed on the HKEx and 10 companies have been listed on the STAR Market. See the table below for details:

S/N	Company name	Stock Exchange	Capital Raised	Business area
1	Akeso,Inc	HKEx	Over $300 million	Tumour、Autoimmune disease
2	Innocare	HKEx	About HK$2.093 billion	Cancer、Autoimmune disease
3	Kintor Pharmaceutical Limited	HKEx	About $240 million	Prostate Cancer、Breast Cancer Liver cancer、Baldness
4	Zai Lab Limited	HKEx	HK$5.73 billion	Tumour、Autoimmune disease
5	Immunotech Biopharm Ltd	HKEx	HK$1.0241 billion	T-Cell Immunotherapy
6	Ocumension Therapeutics	HKEx	HK$1.553 billion	Ophthalmology
7	Hepalink	HKEx	HK$3.8 billion	Heparin、Tumour
8	Jhbp (Cy) Holdings Limited	HKEx	-----	Tumour、Autoimmune disease
9	Everest Medicines Limited	HKEx	-----	Tumour、Autoimmune disease Cardiorenal diseases Infectious disease
10	Simcere Pharmaceutical Group Limited	HKEx	-----	Tumour、Central nervous system diseases、Autoimmune disease
11	Jw (Cayman) Therapeutics Co. Ltd	HKEx	-----	CAR-T
12	Remegen Co. Ltd.	HKEx	-----	Autoimmune disease、Tumour Ophthalmology
13	Antengene Corporation Limited	HKEx	-----	Tumour
14	Zelgen	STAR Market	About ¥2.026 billion	Tumour、Hematopathy Hepatobiliary disease
15	Bio-Thera Solutions, Ltd	STAR Market	About ¥2.0 billion	Tumour、Autoimmune disease
16	Sinocelltech Grou Limited	STAR Market	About ¥1.282 billion	Monoclonal Antibody Recombination Protein、Vaccine
17	HitGen Inc.	STAR Market	About ¥830 million	The lead drug
18	Cansino Biologics Inc.	STAR Market	About ¥5.2 billion	Vaccine
19	Sunshine Guojian Pharmaceutical(shanghai) Co. Ltd.	STAR Market	¥3.183 billion	Antibody
20	Jiangsu Aidea Pharmaceutical Co.,ltd	STAR Market	¥839.4 million	Antidote、Tumour
21	Junshi BiosciencesCo., Ltd.	STAR Market	About ¥2.7 billion	Tumour、Chronic disease Autoimmune disease
22	Easton BioPharmaceuticals Co.,Ltd	STAR Market	¥1.335 billion	Combination of generic drug development
23	Frontier Biotechnologies Inc	STAR Market	¥1.845 billion	AIDS antiviral treatment. Pain therapy

In addition to the companies listed in the above table, other biopharmaceutical companies such as Beijing Science Sun Pharmaceutical Co.,LTD、Changchun BCHT Biotechnology Co and other companies have also submitted IPO applications to the HKEx and the STAR Market

Keyword:

Previous: RCEP全文发布，多项知识产权规定值得关注！

Next: 3D Medicines obtains exclusive development and commercialization authorization for new anti-cancer drugs in Greater China

Previous: RCEP全文发布，多项知识产权规定值得关注！

Next: 3D Medicines obtains exclusive development and commercialization authorization for new anti-cancer drugs in Greater China

Electronic Arts pledges free use for five accessibility patents

Electronic Arts pledges free use for five accessibility patents Recently, Electronic Arts (EA) announced a patent pledge that gives other companies and developers free access to five of its current accessibility-related patents and technology. The company promised not to enforce against any party for infringing any of the listed patents. Instead, EA hopes to encourage “innovation” and build new features that make video games more inclusive on a much larger scale by opening up the patents. Electronic Arts (EA) is an American video game company founded in 1982. The company owns many popular and famous games, such as The Sims, SimCity, Apex Legends, Madden NFL and FIFA. Each of the games has more than 30 or 50 million sales volume. Significantly, esports involves FIFA and Apex Legends into the event list. Apex Legends has up to 1 billion players, and it is so popular that it has a Switch version. Within the freely available patents, one of which grabs everyone’s attention -- Apex Legends’ ping system (patent No. US 11097189). The ping system in Apex Legends, which excellently allows players to make communication and teamwork quick and easy without hearing or speaking, has been praised both as an impressive alternative to voice chat and as a great accessibility feature for players with a variety of disabilities. The other patents include the technology widely used in the FIFA and Madden NFL. The innovations can automatically detect and modify colors (patent No. US 10118097 and CN 107694092) and contrast ratios (patent No. US 10878540) to improve gamers’ visibility with colorblindness and low vision. Furthermore, one of the patents relates to personalized sound technology, helping players with hearing issues by modifying or creating music based on their preferences (patent No. US 10790919). The code of the mentioned technology is published on EA’s GitHub, and it is open to all developers. Thus, the developers can use it or adapt it for their games without spending the costs to research. It is good that EA shares the patents for free use and aims to create an accessibility-increased gaming environment for players. However, it is not “unconditional” to use the listed patents. In the pledge, EA mentioned that it may terminate the promise for a specific party which files a patent infringement lawsuit or other patent proceedings against EA. We can see parts of EV’s ambition behind the announcement—to build a large game developer league and a community of shared interests. Reference: https://www.ea.com/commitments/positive-play/accessibility-patent-pledge https://iknow.stpi.narl.org.tw/Post/Read.aspx?PostID=14562 https://www.polygon.com/22639469/apex-legends-electronic-arts-patent-pledge-accessibility-developers https://www.theverge.com/2021/8/24/22638535/ea-accessibility-patent-pledge-apex-legends-ping-system https://www.gamesradar.com/ea-secures-a-patent-for-the-apex-legends-ping-system-and-its-giving-it-away-for-free/ https://dotesports.com/apex-legends/news/apex-legends-ping-system-is-now-patent-free-for-accessibility https://www.nintendolife.com/news/2021/08/apex_legends_ping_system_now_patent-free_as_ea_announces_accessibility_pledge Recently, Electronic Arts (EA) announced a patent pledge that gives other companies and developers free access to five of its current accessibility-related patents and technology. The company promised not to enforce against any party for infringing any of the listed patents. Instead, EA hopes to encourage “innovation” and build new features that make video games more inclusive on a much larger scale by opening up the patents. Electronic Arts (EA) is an American video game company founded in 1982. The company owns many popular and famous games, such as The Sims, SimCity, Apex Legends, Madden NFL and FIFA. Each of the games has more than 30 or 50 million sales volume. Significantly, esports involves FIFA and Apex Legends into the event list. Apex Legends has up to 1 billion players, and it is so popular that it has a Switch version. Within the freely available patents, one of which grabs everyone’s attention -- Apex Legends’ ping system (patent No. US 11097189). The ping system in Apex Legends, which excellently allows players to make communication and teamwork quick and easy without hearing or speaking, has been praised both as an impressive alternative to voice chat and as a great accessibility feature for players with a variety of disabilities. The other patents include the technology widely used in the FIFA and Madden NFL. The innovations can automatically detect and modify colors (patent No. US 10118097 and CN 107694092) and contrast ratios (patent No. US 10878540) to improve gamers’ visibility with colorblindness and low vision. Furthermore, one of the patents relates to personalized sound technology, helping players with hearing issues by modifying or creating music based on their preferences (patent No. US 10790919). The

2021-10-22

The forum on "China's Intellectual Property-related Reform Measures and New Trends in Patent Litigation" will be held successfully!

The forum on "China's Intellectual Property-related Reform Measures and New Trends in Patent Litigation" will be held successfully! In response to the call for building a strong country with intellectual property rights, at 2 o'clock in the afternoon of October 21, the forum on "China's reform measures related to intellectual property rights and new trends in patent litigation" will be successfully held in Nanjing Jiangbei New District Industrial Technology Research and Innovation Park. The event was hosted by the Science and Technology Innovation Bureau of Nanjing Jiangbei New Area Management Committee, Nanjing Jiangbei New Area Industrial Technology Research and Innovation Park, Nanjing Intellectual Property Rights Protection Assistance Center Jiangbei New District Center, Nanjing Huaxun Intellectual Property Consultant Co., Ltd., Nanjing Intellectual Property Co-organized by the Protection Center (Nanjing Intellectual Property Rights Protection Assistance Center), Taiwan Pharmaceutical Development Association, and Gene Online. The director of Nanjing Intellectual Property Protection Center, Mou Xiaojian, delivered a speech. Director Mu expressed his warm congratulations on the holding of this event and introduced in detail the new pattern of intellectual property protection in Nanjing. He said: At present, Nanjing has implemented a rights protection assistance network in the municipal area. With full coverage, Nanjing Intellectual Property Protection Center is willing to closely communicate and interact with Nanjing's innovation entities, and provide relevant public welfare services such as rapid pre-review, rapid rights protection, and comprehensive utilization for enterprises in need. In addition, Huang Funan, CEO of Gene Online, was unable to come to congratulate due to the epidemic, and recorded a congratulatory video. In the video, he said: China Innovative Pharmaceuticals has already made many outstanding achievements on the international stage, and these are inseparable from intellectual property rights. The support of the company can also show the importance of intellectual property rights to biotechnology and pharmaceutical companies. This event invites four industry experts to focus on China's reform measures related to intellectual property rights and new trends in patent litigation, discuss with companies and universities, and make arrangements in advance. Dr. Qingchen Hou, general manager of Nanjing Huaxun Intellectual Property Consulting Co., Ltd., introduced the "Guidelines for Building a Powerful Country with Intellectual Property Rights (2021-2035)" and explained his views from four aspects: background, strategic layout, overall requirements, and organizational guarantees. . Subsequently, a detailed analysis of China's patent linkage system was carried out, and compared with the same types of cases at home and abroad, questions were raised: Why should we reward the first person who successfully challenged patents? Not the first person to file a P4 application? And have a series of discussions with you. Director Jiang Haijun of the Intellectual Property Protection Legal Committee of the Nanjing Lawyers Association gave a speech on three points: the problems after the amendment of the patent law, the enforceability of the amount of compensation, and the legal conflicts related to service inventions. Regarding the patent right evaluation report, he emphasized that the patentee, interested party or accused infringer can also proactively issue a patent right evaluation report. "Patent is a work of art that combines technology and law" is a message shared by Mr. Feng Tao from Jiangsu Junbo Law Firm at this event. Mr. Feng analyzes the big data of Chinese patent litigation cases through graphs and examples. Explore. The last topic of the event was shared by Guo Huangying, Intellectual Property Manager of Nanjing Huaxun Intellectual Property Agency (General Partnership)-China's Patent Infringement Judgment Principles and New Developments. Manager Guo explained to everyone the principles of patent infringement judgment and the necessity of patent infringement search and analysis before producing and selling products. In the intellectual property industry, ECCOM has been providing high-quality and professional comprehensive intellectual property services to enterprises and universities one step at a time. It also hopes that under the leadership of the state and the government, it will contribute to the building of a strong intellectual property nation in China. Make a contribution.

2021-10-22

Types of patents that are easily overlooked- Design Patent

Types of patents that are easily overlooked- Design Patent In recent years, as the public’s awareness of intellectual property has increased, people have begun to consciously use the patent law to protect their intellectual property rights. However, in the process of implementation, they often only focus on invention patent and utility model patent, and tend to ignore the protection of design patent. Recently, Midea sued Haotaitai for two models of CXW-300-D998 and CXW-300-D908 Haotaitai brand range hoods In the case of suspected infringement of its design patent (patent number: ZL201930621598.X), the Guangzhou Intellectual Property Court made a first-instance judgment after hearing that it determined that the two products of Haotaitai constituted infringement, and ordered it to immediately stop the infringement and compensate Midea, The company's economic losses and reasonable expenses totaled 360,000 yuan. In fact, appearance infringement cases have occurred from time to time before, such as: "Molly" blind box design patent case, "Siemens" switch design patent infringement dispute case received a compensation of 6 million yuan, three Casio watch design patents were infringed Received a compensation of 8.8 million yuan and so on. The reason why people ignore the protection of design patents, in the final analysis, is that they have insufficient knowledge of design patents. Today, let's take a look at what is protected by design patents and what rights protections can we apply for? Design patent definition: Article 2 of the "Patent Law", design patent, refers to a new design that is aesthetically pleasing and suitable for industrial applications based on the shape, pattern, or combination of products, and the combination of color, shape, and pattern. Protected range: The shape of the product; the pattern of the product; the shape and pattern of the product; the shape and color of the product; the pattern and color of the product; the shape, pattern and color of the product. Protection period: The term of protection for design patent rights is 15 years, calculated from the date of filing. What are the conditions for applying for a design patent? The design should be aesthetically pleasing Appearance patents should be suitable for industrial applications The design patent application should be novel The design patent application should be inventiveness What are the advantages and functions of design patents? Protect the rights and interests of enterprises in product designs and fight against infringements in market competition. To enhance brand value, the quality and quantity of patents are the embodiment of the company's innovation ability and core competitiveness. Receive consumer recognition. If a company's new product appearance is filed for a patent in a timely manner, its appearance design will enjoy the exclusive right. Nowadays, consumers often choose products with trendy and beautiful appearance when buying their products. Applying for a design patent is a necessary condition for applying for a high-tech enterprise.

2021-09-26

Colopl Settles Patent Infringement Lawsuit with Nintendo by Paying $30 Million

Colopl Settles Patent Infringement Lawsuit with Nintendo by Paying $30 Million This August, Nintendo and a game developer Colopl announced that they have settled for patent infringement regarding White Cat Project (Shironeko Project in Japanese), a smartphone game developed by Colopl. Although both companies did not publicly share exact details of the settlement, at least it is sure that Colopl agreed to pay 3.3 billion yen (about US$30.2 million) as the settlement fee for the proceedings, including the future license of Nintendo's patents. How did the battle begin? Being developed and published by a Japanese game developer, Colopl, White Cat Project is a free-to-play action role-playing game for Android and iOS systems. The mobile game was launched in July 2014 as well as got a television anime adaptation in 2020. It is incredibly popular to have more than 50 million downloads. Furthermore, the game is set to receive a Switch version titled "Shironeko New Project". In September 2016, Nintendo noted the Colopl's game and considered that the game had infringed on several of Nintendo's technology patents. The two companies communicated with each other for over a year; however, Nintendo did not accept the explanations from Colopl, and Nintendo filed a lawsuit against Colopl at the beginning of 2018. Nintendo claimed that Colopl infringed 6 of its patents. These patents protect touch-screen joystick functionality (patent no. JP3734820), multiplayer connectivity (patent no. JP5595991, JP6271692), confirmation screens in sleep mode (patent no. JP4010533), character attacks based on touch input locations (patent no. JP4262217), and a shadow effect placed on characters hidden behind the game geometry (patent no. JP3637031). These patents almost cover various ways of game technology, especially the patent JP5595991 and JP6271692. Their patent family is wide-reaching, and many divisional applications of the family are pending in Japan. They protect a communication game system and its related devices. It is not easy to detect the patent's existence and boundary since this kind of hardcore technique is so common in the gaming field and our daily lives. The five-year patent war has been settled. After a five-year dispute, the situation appeared to turn in Nintendo's favor as the Switch maker increased its monetary demands, which convinced Colopl to strike a deal that lets it use the disputed patents. Furthermore, a Switch version of White Cat Project remains in the works at Colopl. With the extraordinary losses of Colopl, the legal battle between the two companies came to an end.

2021-09-09